Regentis Biomaterials Launches Phase III Pivotal Trial of GelrinC

Regentis Biomaterials commenced first surgeries in its Phase III pivotal clinical trial of GelrinC biodegradable hydrogel for the treatment of focal knee cartilage defects. Three procedures occurred in the U.S. and Denmark.

The FDA-approved Investigational Device Exemption study is comparing GelrinC to microfracture, the standard of care, and...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us